A growing appetite exists within the pharmaceutical industry for AI to deliver instant results like manuscripts and insights. This "magic button" expectation overlooks the nuance required, forcing communication experts to manage expectations and emphasize AI's role as a human-augmenting tool, not a replacement.

For new technologies to gain adoption in pharma, the central value proposition must be about de-risking decisions. Leaders and regulators often view the technology as a "black box" and are less concerned with its mechanics than with its ability to give them confidence in making safer, more reliable choices.

The rise of AI doesn't change your team's fundamental goals. Leaders should demystify AI by positioning it as just another powerful tool, similar to past technological shifts. The core work remains the same; AI just helps you do it better and faster.

AI delivers the most value when applied to mature, well-understood processes, not chaotic ones. Pharma's MLR (Medical, Legal, Regulatory) review is a prime candidate for AI disruption precisely because its established, structured nature provides the necessary guardrails and historical data for AI to be effective.

Regulators like the FDA are actively encouraging the use of AI to improve clinical trial success rates. However, pharmaceutical companies are hesitant to adopt these innovative methods, fearing that any deviation from traditional processes will lead to costly delays or orders to restart the trial.

To overcome resistance to AI in critical fields like healthcare, position it first as a supplement, not a replacement. By providing AI-generated summaries that still require clinical review, organizations can demonstrate value and build trust, making clinicians see AI as a tool that frees them for high-value work.

The pharmaceutical industry risks repeating Kodak's failure of inventing but ignoring a disruptive technology. For Kodak, it was digital photography; for pharma, it's AI. The industry possesses vast amounts of data (the new 'film'), but the real danger lies in failing to embrace the AI-driven intelligence layer that can interpret and act on it.

The path to enterprise AI adoption follows a typical change curve. To bypass initial fear and rejection, organizations should first apply AI to transform familiar, high-friction workflows. This strategy builds momentum and demonstrates value before tackling entirely new, innovative business models.

Pharmaceutical giants are adopting AI not for moonshot "cure cancer" prompts, but to streamline critical, error-prone processes like compiling 10,000-page FDA documents. This mundane application prevents costly delays and accelerates time-to-market for multi-billion dollar drugs.